Welcome to our dedicated page for Camtek SEC filings (Ticker: CAMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Semiconductor tools mean dense disclosures. Camtek’s 10-K spans intricate discussions on wafer-level metrology, export controls and customer concentration—details investors can’t afford to miss. Yet combing through hundreds of pages to understand revenue tied to advanced packaging or to track when executives sell stock is time-consuming.
Stock Titan solves that problem. Our AI reads every Camtek SEC filings explained simply, surfaces the metrics that move the share price, and delivers real-time alerts the moment a Camtek Form 4 insider transactions real-time notice hits EDGAR. Whether you’re looking for the next Camtek quarterly earnings report 10-Q filing, an unexpected Camtek 8-K material events explained, or the full Camtek annual report 10-K simplified, you’ll find it here—annotated, summarized and searchable.
Use our platform to:
- Track Camtek insider trading Form 4 transactions and spot buying or selling before material announcements
- Compare margin trends with AI-generated Camtek earnings report filing analysis
- Review Camtek proxy statement executive compensation without wading through boilerplate tables
- Monitor supply-chain risks flagged in 8-K filings
Q2 2025 highlights: Camtek posted record revenue of $123.3 m (+20% YoY). GAAP gross margin 50.8%; non-GAAP 51.9%. GAAP operating income $32.0 m (+24%); non-GAAP $37.4 m (30.3% margin). GAAP net income $33.7 m (+21%), diluted EPS $0.69; non-GAAP EPS $0.79. Cash, deposits & securities climbed to $543.9 m, fuelled by $23.5 m operating cash flow.
Guidance & strategy: Management targets Q3 revenue of ≈$125 m, placing the company on a $0.5 bn annual run-rate. Growth is tied to AI-driven advanced-packaging demand; newly launched Eagle G5 and Hawk inspection systems are seeing strong market reception.
Balance-sheet snapshot: Assets $974.7 m, equity $626.5 m, convertible notes $198.5 m. R&D and SG&A costs rose YoY but remain supportive of expanding top-line and 51-52% gross-margin profile.